Program Description
T-cell engaging bispecific antibodies (BsAbs) drive focused immune response to tumor antigen-presenting cells. T-cell engaging BsAbs utilize antibodies with specificity for anti-CD3 and tumor-associated antigens to produce functionality. As BsAbs are integrated into an increasingly complex treatment paradigm for relapsed and refractory hematologic malignancies, pharmacists play essential and varied roles as part of the multidisciplinary care team to ensure optimal patient outcomes. The panel of experts will share perspectives on proactive approaches to overcome operational challenges associated with the placement of BsAbs in the treatment of hematologic malignancies. Strategies for safe implementation of BsAbs into treatment paradigms, including selection of therapy, preparation of products, and monitoring of patients, will be highlighted through discussions of patient cases.
Target audience: Health-system and oncology pharmacists
Type of activity: Application
Release date: January 26, 2023
Expiration date: March 26, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify operational barriers to the safe and effective integration of bispecific antibodies (BsAbs) within the treatment paradigm of hematologic malignancies
- Explore strategies to overcome administrative challenges associated with the use of BsAbs in cancer care
- Illustrate management of common and serious toxicities of BsAbs through early recognition, accurate grading, and appropriate treatment strategies
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist - Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee
James A. Davis, PharmD, BCOP
Assistant Professor and Clinical Pharmacy Specialist – Malignant Hematology
MUSC College of Pharmacy
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina
Sara Moran Smith, PharmD, BCOP
Oncology Pharmacy Program Manager
Allina Health
Minneapolis, Minnesota
Jane de Lartigue, PhD
Medical Writer for Discussion Guide
Freelance Medical Writer
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-612-L01-P. The activity is available for CE credit through February 14, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Allison R. Butts, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: AstraZeneca, BeyondSpring Pharmaceuticals
Michael J. Berger, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Consultant: Eli Lilly advisory board – Verzenio
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms